Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
Adial Pharmaceuticals (NASDAQ: ADIL) has been granted a new U.S. patent (No. 12,226,401) on February 18, 2025, expanding its genetic-based approach to treating and diagnosing alcohol use disorder and drug dependencies. The patent covers methods for identifying genetic markers in patients with alcohol or opioid-related disorders.
The patent specifically focuses on identifying genotypes including the AC genotype of rs17614942 in the HTR3B gene and the AG genotype of rs1150226 in the HTR3A gene. This advancement will enable healthcare providers to develop tailored treatment plans using AD04, Adial's investigational drug product. The precision medicine approach aims to optimize treatment outcomes while minimizing risks associated with standardized treatments.
Adial Pharmaceuticals (NASDAQ: ADIL) ha ottenuto un nuovo brevetto statunitense (No. 12,226,401) il 18 febbraio 2025, ampliando il suo approccio basato sulla genetica per il trattamento e la diagnosi dei disturbi da uso di alcol e delle dipendenze da droghe. Il brevetto copre i metodi per identificare i marcatori genetici nei pazienti con disturbi correlati all'alcol o agli oppioidi.
Il brevetto si concentra specificamente sull'identificazione dei genotipi, inclusi il genotipo AC di rs17614942 nel gene HTR3B e il genotipo AG di rs1150226 nel gene HTR3A. Questo progresso consentirà ai fornitori di assistenza sanitaria di sviluppare piani di trattamento personalizzati utilizzando AD04, il prodotto farmaceutico sperimentale di Adial. L'approccio della medicina di precisione mira a ottimizzare i risultati terapeutici riducendo al minimo i rischi associati ai trattamenti standardizzati.
Adial Pharmaceuticals (NASDAQ: ADIL) ha recibido una nueva patente en EE. UU. (No. 12,226,401) el 18 de febrero de 2025, ampliando su enfoque basado en la genética para tratar y diagnosticar el trastorno por consumo de alcohol y las dependencias de drogas. La patente cubre métodos para identificar marcadores genéticos en pacientes con trastornos relacionados con el alcohol o los opioides.
La patente se centra específicamente en la identificación de genotipos, incluidos el genotipo AC de rs17614942 en el gen HTR3B y el genotipo AG de rs1150226 en el gen HTR3A. Este avance permitirá a los proveedores de atención médica desarrollar planes de tratamiento personalizados utilizando AD04, el producto farmacéutico en investigación de Adial. El enfoque de medicina de precisión tiene como objetivo optimizar los resultados del tratamiento mientras minimiza los riesgos asociados con los tratamientos estandarizados.
Adial Pharmaceuticals (NASDAQ: ADIL)는 2025년 2월 18일 미국에서 새로운 특허(번호 12,226,401)를 획득하여 알코올 사용 장애 및 약물 의존증 치료 및 진단을 위한 유전자 기반 접근 방식을 확장했습니다. 이 특허는 알코올 또는 오피오이드 관련 장애가 있는 환자의 유전자 마커를 식별하는 방법을 포함합니다.
특허는 HTR3B 유전자에서 rs17614942의 AC 유전자형과 HTR3A 유전자에서 rs1150226의 AG 유전자형을 식별하는 데 특히 중점을 두고 있습니다. 이러한 발전은 의료 제공자가 Adial의 임상 시험 약물인 AD04를 사용하여 맞춤형 치료 계획을 개발할 수 있도록 합니다. 정밀 의학 접근법은 표준화된 치료와 관련된 위험을 최소화하면서 치료 결과를 최적화하는 것을 목표로 합니다.
Adial Pharmaceuticals (NASDAQ: ADIL) a obtenu un nouveau brevet américain (n° 12,226,401) le 18 février 2025, élargissant son approche génétique pour traiter et diagnostiquer les troubles liés à l'usage d'alcool et les dépendances aux drogues. Le brevet couvre des méthodes pour identifier des marqueurs génétiques chez les patients présentant des troubles liés à l'alcool ou aux opioïdes.
Le brevet se concentre spécifiquement sur l'identification des génotypes, y compris le génotype AC de rs17614942 dans le gène HTR3B et le génotype AG de rs1150226 dans le gène HTR3A. Cette avancée permettra aux professionnels de la santé de développer des plans de traitement personnalisés en utilisant AD04, le produit pharmaceutique expérimental d'Adial. L'approche de médecine de précision vise à optimiser les résultats thérapeutiques tout en minimisant les risques associés aux traitements standardisés.
Adial Pharmaceuticals (NASDAQ: ADIL) hat am 18. Februar 2025 ein neues US-Patent (Nr. 12,226,401) erhalten, das ihren genetischen Ansatz zur Behandlung und Diagnose von Alkoholgebrauchsstörungen und Drogenabhängigkeiten erweitert. Das Patent umfasst Methoden zur Identifizierung genetischer Marker bei Patienten mit alkohol- oder opioidgebundenen Störungen.
Das Patent konzentriert sich speziell auf die Identifizierung von Genotypen, einschließlich des AC-Genotyps von rs17614942 im HTR3B-Gen und des AG-Genotyps von rs1150226 im HTR3A-Gen. Dieser Fortschritt wird es den Gesundheitsdienstleistern ermöglichen, maßgeschneiderte Behandlungspläne unter Verwendung von AD04, dem Prüfpräparat von Adial, zu entwickeln. Der Ansatz der Präzisionsmedizin zielt darauf ab, die Behandlungsergebnisse zu optimieren und gleichzeitig die mit standardisierten Behandlungen verbundenen Risiken zu minimieren.
- New patent strengthens intellectual property portfolio for genetic-based addiction treatment
- Patent expands potential patient base for AD04 drug through genetic marker identification
- Technology enables personalized treatment plans based on genetic profiles
- AD04 remains an investigational drug without current market approval
- Commercial viability and market acceptance of genetic-based approach remains unproven
Insights
The newly granted USPTO patent significantly strengthens Adial Pharmaceuticals' intellectual property position in the precision medicine approach to addiction treatment. The patent's scope is particularly valuable as it covers both diagnostic and therapeutic applications, creating multiple potential revenue streams through both testing and treatment pathways.
The patent's focus on specific genetic markers (rs17614942 in HTR3B and rs1150226 in HTR3A) provides several strategic advantages:
- Enhanced patient selection capabilities for clinical trials, potentially improving success rates and reducing development costs
- Creation of a companion diagnostic opportunity, which could generate additional revenue streams
- Potential for premium pricing through demonstrated superior efficacy in genetically-matched patients
- Barriers to entry for competitors in the personalized addiction treatment space
This patent's timing is strategic, as it comes when precision medicine approaches are gaining traction in various therapeutic areas. For Adial, with its micro-cap status, this intellectual property protection is important for maintaining competitive advantages and potentially attracting partnership opportunities. The expanded coverage to include opioid-related disorders significantly increases the addressable market beyond alcohol use disorder, though this will require additional clinical validation.
However, investors should note that while patent protection is crucial, the company still faces significant challenges: the need for successful clinical trials, regulatory approvals, and substantial capital for commercialization. The patent's value will ultimately depend on the clinical success of AD04 and the company's ability to effectively commercialize both the diagnostic and therapeutic aspects of their technology.
New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders
Patent expands the identification of potential treatment candidates for AD04 administration based on the patient’s unique genetic profile
GLEN ALLEN, Va., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12,226,401 was issued on February 18, 2025 by the United States Patent and Trademark Office (USPTO) expanding coverage of Adial’s genetic-based approach to treating and diagnosing alcohol use disorder and other drug dependencies.
The new patent covers claims that focus on a method for identifying genetic markers in patients with alcohol or opioid-related disorders. With the identification of specific genotypes, including the AC genotype of rs17614942 in the HTR3B gene and the AG genotype of rs1150226 in the HTR3A gene, providers will be able to provide tailored treatment plans using AD04, the Company’s investigational new drug product. This patent also expands the identification of possible treatment candidates for AD04 administration depending on the patient’s unique genetic profile. By aligning therapeutic approaches with genetic data, the AD04 precision medicine approach is designed to deliver optimal outcomes while reducing risks associated with one-size-fits-all approaches.
“This patent demonstrates our continued dedication to advancing science-driven solutions for diagnosing and treating addiction,” said Cary Claiborne, CEO of Adial Pharmaceuticals. “Our patented approach, which uses genetic information to guide treatment, has the potential to transform how alcohol and opioid dependence are treated. We believe this personalized method not only enhances effectiveness but also provides new options to millions suffering from addiction by addressing the root causes on a molecular level.”
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
If you are interested in exploring partnership opportunities with Adial, we invite you to reach out to us (BD@adialpharma.com) to discuss how our joint efforts can bring about positive change to the millions of patients who are struggling with addiction.
Forward-Looking Statements
This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding providers being able to provide tailored treatment plans using AD04 with the identification of specific genotypes, including the AC genotype of rs17614942 in the HTR3B gene and the AG genotype of rs1150226 in the HTR3A gene, delivering optimal outcomes while reducing risks associated with one-size-fits-all approaches by aligning therapeutic approaches with genetic data, advancing science-driven solutions for diagnosing and treating addiction, the Company’s patented approach having the potential to transform how alcohol and opioid dependence are treated, the Company’s personalized method not only enhancing effectiveness but also providing new options to millions suffering from addiction by addressing the root causes on a molecular level and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: ADIL@crescendo-ir.com
FAQ
What does Adial's (ADIL) new patent cover for addiction treatment?
How will ADIL's new patent impact addiction treatment?
What genetic markers does ADIL's new patent identify for addiction treatment?
When was Adial Pharmaceuticals' (ADIL) new genetic marker patent issued?
